+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-04-05Number of Pages: 103

Transdermal Scopolamine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Chapter 1.  Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2.  Assumptions and Research Methodology

Chapter 3.  Executive Summary: Global Transdermal Scopolamine Market         

Chapter 4.  Market Overview
4.1. Introduction
       4.1.1. Scopolamine Indications
       4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Key Market Indicators
4.4. Market Dynamics
       4.4.1. Drivers
       4.4.2. Restraints
       4.4.3. Opportunities
4.5. Global Transdermal Scopolamine Market Analysis and Forecast, 2016 – 2024
       4.5.1. Market Revenue Projections (US$ Mn)
4.6. Porter’s five forces analysis
4.7. Value Chain Analysis
4.8. Market Outlook
4.9. Global Company Share Analysis – 2016 (Estimated)
4.10. Scopolamine Product Prescription Rate by Region (%)
       4.10.1. Oral
       4.10.2. Injections
       4.10.3. Transdermal / Patch
4.11. Pipeline Analysis – Transdermal Scopolamine

Chapter 5.  Global Transdermal Scopolamine Market Analysis and Forecasts, By Region
5.1. Key Findings
5.2. Policies and Regulations
5.3. Market Size (US$ Mn) Forecast By Region
       5.3.1. North America
       5.3.2. Europe
       5.3.3. Asia Pacific        
       5.3.4. Latin America
       5.3.5. Middle East and Africa
5.4. Market Attractiveness By Region

Chapter 6.  North America Transdermal Scopolamine Market Analysis and Forecast
6.1. Introduction
       6.1.1. Key Findings
       6.1.2. Policies and Regulations
       6.1.3. Price Trend Analysis
       6.1.4. Key Trends
6.2. Market Size (US$ Mn) Forecast, By Country
       6.2.1. U.S.
       6.2.2. Canada
6.3. Market Attractiveness Analysis By Country

Chapter 7.  Europe Transdermal Scopolamine Market Analysis and Forecast
7.1. Introduction
       7.1.1. Key Findings
       7.1.2. Policies and Regulations
       7.1.3. Price Trend Analysis
       7.1.4. Key Trends
7.2. Market Size (US$ Mn) Forecast, By Country
       7.2.1. Germany
       7.2.2. France
       7.2.3. U.K.
       7.2.4. Spain
       7.2.5. Italy
       7.2.6. Rest of Europe
7.3. Market Attractiveness Analysis By Country 

Chapter 8.  Asia Pacific Transdermal Scopolamine Market Analysis and Forecast
8.1. Introduction
       8.1.1. Key Findings       
       8.1.2. Policies and Regulations
       8.1.3. Price Trend Analysis       
       8.1.4. Key Trends
8.2. Market Size (US$ Mn) Forecast, By Country
       8.2.1. Japan
       8.2.2. China
       8.2.3. India
       8.2.4. Australia
       8.2.5. Rest of Asia Pacific
8.3. Market Attractiveness Analysis By Country 

Chapter 9.  Latin America Transdermal Scopolamine Market  Analysis and Forecast
9.1. Introduction
       9.1.1. Key Findings
       9.1.2. Policies and Regulations
       9.1.3. Price Trend Analysis
       9.1.4. Key Trends
9.2. Market Size (US$ Mn) Forecast, By Country
       9.2.1. Brazil
       9.2.2. Mexico
       9.2.3. Rest of Latin America
9.3. Market Attractiveness Analysis By Country 

Chapter 10.  Middle East & Africa Transdermal Scopolamine Market  Analysis and Forecast
10.1. Introduction
       10.1.1. Key Findings
       10.1.2. Policies and Regulations
       10.1.3. Price Trend Analysis
       10.1.4. Key Trends
10.2. Market Size (US$ Mn) Forecast, By Country
       10.2.1. GCC Countries
       10.2.2. South Africa
       10.2.3. Rest of Middle East and Africa
10.3. Market Attractiveness Analysis By Country 

Chapter 11.  Competition Landscape
11.1. Transdermal Scopolamine Market – Competition Matrix (By Tier and Size of companies) (2015)
11.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
       11.2.1. Baxter International Inc.
                 11.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                 11.2.1.2. Product Portfolio
                 11.2.1.3. SWOT Analysis
                 11.2.1.4. Financial Overview
                 11.2.1.5. Strategic Overview
       11.2.2. GlaxoSmithKline plc
                 11.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                 11.2.2.2. Product Portfolio
                 11.2.2.3. SWOT Analysis
                 11.2.2.4. Financial Overview
                 11.2.2.5. Strategic Overview
       11.2.3. Novartis AG
                 11.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                 11.2.3.2. Product Portfolio
                 11.2.3.3. SWOT Analysis
                 11.2.3.4. Financial Overview
                 11.2.3.5. Strategic Overview
       11.2.4. Perrigo Company plc.
                 11.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                 11.2.4.2. Product Portfolio
                 11.2.4.3. SWOT Analysis
                 11.2.4.4. Financial Overview
                 11.2.4.5. Strategic Overview
       11.2.5. Caleb Pharmaceuticals, Inc.
                 11.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                 11.2.5.2. Product Portfolio
                 11.2.5.3. SWOT Analysis
                 11.2.5.4. Financial Overview
                 11.2.5.5. Strategic Overview
       11.2.6. Myungmoon Pharma Co. LTD.
                 11.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                 11.2.6.2. Product Portfolio
                 11.2.6.3. SWOT Analysis
                 11.2.6.4. Financial Overview
                 11.2.6.5. Strategic Overview

Chapter 12.  Key Take Away

List of Figures

Figure 01: Global Transdermal Scopolamine Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 02: Global Transdermal Scopolamine Market Share Analysis, by Company, 2016 (Estimated)
Figure 03: Global Scopolamine Product Prescription Share, by Region
Figure 04: Global Transdermal Scopolamine Market Value Share Analysis, by Region, 2015 and 2024
Figure 05: Global Transdermal Scopolamine Market Attractiveness Analysis, by Region
Figure 06: North America Transdermal Scopolamine Market Value Share Analysis, by Country, 2015 and 2024
Figure 07: North America Transdermal Scopolamine Market Attractiveness Analysis, by Country
Figure 08: Europe Transdermal Scopolamine Market Value Share Analysis, by Country / Sub-region, 2015 and 2024
Figure 09: Europe Transdermal Scopolamine Market Attractiveness Analysis, by Country / Sub-region
Figure 10: Asia Pacific Transdermal Scopolamine Market Value Share Analysis, by Country / Sub-region, 2015 and 2024
Figure 11: Asia Pacific Transdermal Scopolamine Market Attractiveness Analysis, by Country / Sub-region
Figure 12: Latin America Transdermal Scopolamine Market Value Share Analysis, by Country / Sub-region, 2015 and 2024
Figure 13: Latin America Transdermal Scopolamine Market Attractiveness Analysis, by Country / Sub-region
Figure 14: MEA Transdermal Scopolamine Market Value Share Analysis, by Country / Sub-region, 2015 and 2024
Figure 15: Middle East & Africa Transdermal Scopolamine Market Attractiveness Analysis, by Country / Sub-region

List of Tables

Table 01: Global Transdermal Scopolamine Market Size (US$ Mn) Forecast, 2015–2024
Table 02: Global Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Region, 2015–2024
Table 03: North America Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Country,
Table 04: Europe Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Country / Sub-region, 2015–2024
Table 05: Asia Pacific Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Country / Sub-region, 2015–2024
Table 06: Latin America Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Country / Sub-region, 2015–2024
Table 07: Middle East & Africa Transdermal Scopolamine Market Size (US$ Mn) Forecast, by Country / Sub-region, 2015–2024


 
 
Back To Top